Pandemblock
Biotechnology Research • 
Helsinki, Uusimaa, Finland • 1-10 Employees
Company overview
| Headquarters | Helsinki, Uusimaa, Finland |
| Website | |
| NAICS | 541714 |
| Founded | 2021 |
| Employees | 1-10 |
Key Contact at Pandemblock
Anna R. Mäkelä
CEO | Founder | Co-Owner
Pandemblock Email Formats
Pandemblock uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@pandemblock.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@pandemblock.com | 100% |
About Pandemblock
Pandemblock is a Finnish biotechnology company dedicated to developing innovative antiviral intranasal inhibitors for better pandemic preparedness and prevention. Our nasal spray product candidates are based on the proprietary Sherpabody-platform, facilitating Pandemblock's mission to revolutionize mucosal protection against entire viral families to prevent future pandemics. We are working determinedly to advance our first product Covidin, an intranasal prophylactic and early therapeutic candidate against SARS-CoV-2, into the clinic.
Pandemblock revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Pandemblock has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Pandemblock has never raised funding before.
United States
United Kingdom
Frequently asked questions
4.8
40,000 users
